Review article · 2024 · Open access
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Molecular Cancer, 23(1), 110 · Published 21 May 2024 · DOI 10.1186/s12943-024-02024-9
In brief
“New-generation advanced PROTACs as potential therapeutic agents in cancer therapy” is a 2024 review article by Chao Wang and 4 co-authors, published in Molecular Cancer. OpenAlex counts 240 citations as of 21 November 2026, which puts it in the top 1% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Molecular Cancer.
- Citations
- 240
- Most cited in
- 2026 (133)
- Field-weighted impact
- 8.00
- References
- 154
- Authors
- 5
Abstract
Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin-proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of PROTACs, with the insufficiently precise degradation of favorable POIs standing out as one of the most formidable obstacles. Recently, there has been exploration of new-generation advanced PROTACs, including small-molecule PROTAC prodrugs, biomacromolecule-PROTAC conjugates, and nano-PROTACs, to improve the in vivo efficacy of PROTACs. These improved PROTACs possess the capability to mitigate undesirable physicochemical characteristics inherent in traditional PROTACs, thereby enhancing their targetability and reducing off-target side effects. The new-generation of advanced PROTACs will mark a pivotal turning point in the realm of targeted protein degradation. In this comprehensive review, we have meticulously summarized the state-of-the-art advancements achieved by these cutting-edge PROTACs, elucidated their underlying design principles, deliberated upon the prevailing challenges encountered, and provided an insightful outlook on future prospects within this burgeoning field.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024). New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Molecular Cancer, 23(1), 110. https://doi.org/10.1186/s12943-024-02024-9
MLA 9
Wang, Chao, et al. “New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.” Molecular Cancer, vol. 23, no. 1, 2024, p. 110. https://doi.org/10.1186/s12943-024-02024-9.
Chicago
Wang, Chao, Yujing Zhang, Wujun Chen, Yudong Wu, and Dongming Xing. 2024. “New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.” Molecular Cancer 23 (1): 110. https://doi.org/10.1186/s12943-024-02024-9.
Harvard
Wang, C. et al. (2024) ‘New-generation advanced PROTACs as potential therapeutic agents in cancer therapy’, Molecular Cancer, 23(1), p. 110. doi:10.1186/s12943-024-02024-9.
IEEE
C. Wang, Y. Zhang, W. Chen, Y. Wu, and D. Xing, “New-generation advanced PROTACs as potential therapeutic agents in cancer therapy,” Molecular Cancer, vol. 23, no. 1, p. 110, 2024, doi: 10.1186/s12943-024-02024-9.
BibTeX
@article{wang2024generation,
title = {{New-generation advanced PROTACs as potential therapeutic agents in cancer therapy}},
author = {Wang, Chao and Zhang, Yujing and Chen, Wujun and Wu, Yudong and Xing, Dongming},
journal = {Molecular Cancer},
year = {2024},
volume = {23},
number = {1},
pages = {110},
doi = {10.1186/s12943-024-02024-9},
url = {https://doi.org/10.1186/s12943-024-02024-9}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 16 | |
| 2025 | 91 | |
| 2026 | 133 |
Its field-weighted citation impact is 8.00: it has been cited 8.00 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- PROTACs
- targeted protein degradation
- E3 ubiquitin ligase
- ubiquitin-proteasome system
- cancer therapy
- drug development challenges
- off-target effects
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024). New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Molecular Cancer, 23(1), 110. https://doi.org/10.1186/s12943-024-02024-9
How many times has this paper been cited?
240 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Molecular Cancer: sign in and open the full text from this page.
Who wrote this paper?
Chao Wang, Yujing Zhang, Wujun Chen, Yudong Wu, Dongming Xing.
What is the DOI of this paper?
10.1186/s12943-024-02024-9, permanently at https://doi.org/10.1186/s12943-024-02024-9. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.